Literature DB >> 22089015

Comparative analysis of SmartArc-based dual arc volumetric-modulated arc radiotherapy (VMAT) versus intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma.

Tsair-Fwu Lee1, Pei-Ju Chao, Hui-Min Ting, Su-Hua Lo, Yu-Wen Wang, Chiu-Ching Tuan, Fu-Min Fang, Te-Jen Su.   

Abstract

The purpose of this study was to evaluate and quantify the planning performance of SmartArc-based volumetric-modulated arc radiotherapy (VMAT) versus fixed-beam intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma (NPC) using a sequential mode treatment plan. The plan quality and performance of dual arc-VMAT (DA-VMAT) using the Pinnacle3 Smart-Arc system (clinical version 9.0; Philips, Fitchburg, WI, USA) were evaluated and compared with those of seven-field (7F)-IMRT in 18 consecutive NPC patients. Analysis parameters included the conformity index (CI) and homogeneity index (HI) for the planning target volume (PTV), maximum and mean dose, normal tissue complication probability (NTCP) for the specified organs at risk (OARs), and comprehensive quality index (CQI) for an overall evaluation in the 11 OARs. Treatment delivery time, monitor units per fraction (MU/fr), and Gamma(3 mm, 3%) evaluations were also analyzed. DA-VMAT achieved similar target coverage and slightly better homogeneity than conventional 7F-IMRT with a similar CI and HI. NTCP values were only significantly lower in the left parotid gland (for xerostomia) for DA-VMAT plans. The mean value of CQI at 0.98 ± 0.02 indicated a 2% benefit in sparing OARs by DA-VMAT. The MU/fr used and average delivery times appeared to show improved efficiencies in DA-VMAT. Each technique demonstrated high accuracy in dose delivery in terms of a high-quality assurance (QA) passing rate (> 98%) of the Gamma(3 mm, 3%) criterion. The major difference between DA-VMAT and 7F-IMRT using a sequential mode for treating NPC cases appears to be improved efficiency, resulting in a faster delivery time and the use of fewer MU/fr.

Entities:  

Mesh:

Year:  2011        PMID: 22089015      PMCID: PMC5718754          DOI: 10.1120/jacmp.v12i4.3587

Source DB:  PubMed          Journal:  J Appl Clin Med Phys        ISSN: 1526-9914            Impact factor:   2.102


  55 in total

1.  An arc-sequencing algorithm for intensity modulated arc therapy.

Authors:  D M Shepard; D Cao; M K N Afghan; M A Earl
Journal:  Med Phys       Date:  2007-02       Impact factor: 4.071

2.  Volumetric modulated arc therapy: IMRT in a single gantry arc.

Authors:  Karl Otto
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

3.  Single-Arc IMRT?

Authors:  Thomas Bortfeld; Steve Webb
Journal:  Phys Med Biol       Date:  2008-12-10       Impact factor: 3.609

4.  Commissioning of volumetric modulated arc therapy (VMAT).

Authors:  James L Bedford; Alan P Warrington
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-01       Impact factor: 7.038

5.  Volumetric arc intensity-modulated therapy for spine body radiotherapy: comparison with static intensity-modulated treatment.

Authors:  Q Jackie Wu; Sua Yoo; John P Kirkpatrick; Danthai Thongphiew; Fang-Fang Yin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-03       Impact factor: 7.038

6.  RapidArc planning and delivery in patients with locally advanced head-and-neck cancer undergoing chemoradiotherapy.

Authors:  Patricia Doornaert; Wilko F A R Verbakel; Michael Bieker; Ben J Slotman; Suresh Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-24       Impact factor: 7.038

7.  Simultaneous integrated boost (SIB) for nasopharynx cancer with helical tomotherapy. A planning study.

Authors:  Claudio Fiorino; Italo Dell'Oca; Alessio Pierelli; Sara Broggi; Giovanni Mauro Cattaneo; Anna Chiara; Elena De Martin; Nadia Di Muzio; Ferruccio Fazio; Riccardo Calandrino
Journal:  Strahlenther Onkol       Date:  2007-09       Impact factor: 3.621

8.  Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques.

Authors:  Antonella Fogliata; Alessandro Clivio; Giorgia Nicolini; Eugenio Vanetti; Luca Cozzi
Journal:  Radiother Oncol       Date:  2008-08-28       Impact factor: 6.280

9.  Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study.

Authors:  Wilko F A R Verbakel; Johan P Cuijpers; Daan Hoffmans; Michael Bieker; Ben J Slotman; Suresh Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-01       Impact factor: 7.038

10.  Simultaneous integrated boost radiotherapy for bilateral breast: a treatment planning and dosimetric comparison for volumetric modulated arc and fixed field intensity modulated therapy.

Authors:  Giorgia Nicolini; Alessandro Clivio; Antonella Fogliata; Eugenio Vanetti; Luca Cozzi
Journal:  Radiat Oncol       Date:  2009-07-24       Impact factor: 3.481

View more
  32 in total

1.  Analyzing the performance of the planning system by use of AAPM TG 119 test cases.

Authors:  L Nithya; N Arunai Nambi Raj; Sasikumar Rathinamuthu; Manish Bhushan Pandey
Journal:  Radiol Phys Technol       Date:  2015-07-04

Review 2.  Current status of IMRT in head and neck cancer.

Authors:  Jaime Gomez-Millan; Jesús Romero Fernández; Jose Antonio Medina Carmona
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-20

3.  On the use of AAA and AcurosXB algorithms for three different stereotactic ablative body radiotherapy (SABR) techniques: Volumetric modulated arc therapy (VMAT), intensity modulated radiation therapy (IMRT) and 3D conformal radiotherapy (3D-CRT).

Authors:  Abdulrahman Tajaldeen; Prabhakar Ramachandran; Salem Alghamdi; Moshi Geso
Journal:  Rep Pract Oncol Radiother       Date:  2019-03-23

4.  Comparison of Radiation-Induced Secondary Malignancy Risk Between Sequential and Simultaneous Integrated Boost for the Treatment of Nasopharyngeal Carcinoma: Intensity-Modulated Radiotherapy versus Volumetric-Modulated Arc Therapy.

Authors:  Emel Haciislamoglu; Yunus Cinar; Mehmet Eren; Emine Canyilmaz; Fatih Gurcan; Lasif Serdar; Adnan Yoney
Journal:  Cancer Manag Res       Date:  2020-04-08       Impact factor: 3.989

5.  A comparative planning study of step-and-shoot IMRT versus helical tomotherapy for whole-pelvis irradiation in cervical cancer.

Authors:  Imjai Chitapanarux; Ekkasit Tharavichitkul; Wannapa Nobnop; Somsak Wanwilairat; Roy Vongtama; Patrinee Traisathit
Journal:  J Radiat Res       Date:  2015-02-26       Impact factor: 2.724

6.  Treatment of nasopharyngeal carcinoma by tomotherapy: five-year experience.

Authors:  Stephen Wan Leung; Tsair-Fwu Lee
Journal:  Radiat Oncol       Date:  2013-05-01       Impact factor: 3.481

7.  Multi-institutional comparison of volumetric modulated arc therapy vs. intensity-modulated radiation therapy for head-and-neck cancer: a planning study.

Authors:  Andrea Holt; Dirk Van Gestel; Mark P Arends; Erik W Korevaar; Danny Schuring; Martina C Kunze-Busch; Rob Jw Louwe; Corine van Vliet-Vroegindeweij
Journal:  Radiat Oncol       Date:  2013-01-31       Impact factor: 3.481

8.  Phase I/II study of induction chemotherapy plus concurrent chemotherapy and SMART-IMRT-based radiotherapy in locoregionally-advanced nasopharyngeal cancer.

Authors:  Ting-Yong Fan; Jun Xing; Jie Lu; Tong-Hai Liu; Min Xu; Ying-Jie Zhang; Qian Shao; Jian-Bin Li; Jin-Ming Yu
Journal:  Oncol Lett       Date:  2013-01-15       Impact factor: 2.967

9.  Normal tissue complication probability model parameter estimation for xerostomia in head and neck cancer patients based on scintigraphy and quality of life assessments.

Authors:  Tsair-Fwu Lee; Pei-Ju Chao; Hung-Yu Wang; Hsuan-Chih Hsu; PaoShu Chang; Wen-Cheng Chen
Journal:  BMC Cancer       Date:  2012-12-04       Impact factor: 4.430

10.  Advanced nasopharyngeal carcinoma radiotherapy with volumetric modulated arcs and the potential role of flattening filter-free beams.

Authors:  Mingzan Zhuang; Tuodan Zhang; Zhijian Chen; Zhixiong Lin; Derui Li; Xun Peng; Qingchun Qiu; Renhua Wu
Journal:  Radiat Oncol       Date:  2013-05-14       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.